Shares of Biocon Ltd slipped 4% on Friday, 28 February, after the corporate introduced that their Glucagon-like Peptide-1 (GLP-1) equal, Liraglutide, could be made accessible in the UK. The Liraglutide drug will probably be used to deal with diabetes and weight problems.
With this launch, Biocon will change into the primary generic firm to be approved by the Medicines and Healthcare Merchandise Regulatory Company (MHRA) in the UK for Liraglutide in a major regulated market.
The 2 model names underneath which Biocon’s Liraglutide will probably be marketed are Biocon for Diabetes (a generic type of Victoza) and Biolide for Continual Weight Administration (a generic type of Saxenda).
This mix of drug and gadget has given sufferers with sort 2 diabetes and weight problems, two situations which might be turning into extra prevalent globally, a low-cost various.
Siddharth Mittal, CEO and Managing Director of Biocon, mentioned, “The launch of our gLiraglutide for diabetes and weight problems within the UK marks a major milestone for Biocon. Making this GLP-1 peptide extra accessible and inexpensive to sufferers is a testomony to our unwavering dedication to enhancing healthcare outcomes throughout the globe. The well timed launch will provide healthcare suppliers and sufferers inexpensive entry to this drug and assist fulfill an unmet want.”
Bringing its generic Liraglutide to extra European markets, the US, and some “Markets of the World” (MoW) areas is a significant objective for the enterprise Biocon.
The corporate additionally needs to broaden the vary of GLP-1 peptide compounds in its portfolio to enhance its standing on this shortly rising therapeutic market.
The Position of GLP-1 in Diabetes and Weight Administration GLP-1 receptor agonists, akin to Liraglutide, are generally used to deal with diabetes due to their skill to lower glucagon launch, increase insulin synthesis, and regulate blood sugar ranges.
They assist folks shed extra pounds by lowering starvation and delaying abdomen emptying, which makes them helpful within the therapy of weight problems. The significance of GLP-1 medicines within the therapy of sort 2 diabetes and weight problems is turning into extra broadly acknowledged on account of their rising prevalence.
At 3:30 pm, the shares of Biocon closed 2.87% decrease at Rs 308.90 on NSE.
Navigate Biocon Like a Professional. Ask the Analyst.
Bored with guessing shares to commerce in every day?
Unicorn Alerts empowers you with highly effective instruments like every day inventory scans for Intraday, Swing & Investing, Market Predictions and rather more. Obtain the Unicorn Alerts app at this time and take management of your investments!
